MIT scientists have created a method to "paint" GLP-1 drugs onto antibodies inside the body, achieving longer-lasting effects ...

Pharma giant Novo Nordisk, which makes the obesity drug Wegovy, says the widespread availability of copycat medications is hurting its sales.

Anecdotal reports suggest drugs like Ozempic may curb not just appetite but also impulsive or addictive behaviour, hinting at ...

Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. | Lexicon Pharmaceuticals ...

The race is under way to make faster, cheaper and better GLP-1 drugs that will go beyond reducing obesity levels to treating ...

adult obesity rates dropped for the first time in a decade. Researchers pointed to GLP-1s as a potential contributing factor, alongside pandemic-related… ...

GLP-1 agonists, also known as incretin mimetics, are a class of medication that is primarily used to treat type 2 diabetes and, in some cases, obesity. "The glucagon-like peptide (GLP-1 ...

Despite substantial health benefits, two GLP-1 receptor agonists weren't cost-effective ... ages 20 to 79 who would meet the following obesity clinical trial inclusion criteria: body mass index ...

Although most studies on this topic rely on patient records, a small controlled clinical trial reported last month provided further evidence that GLP-1 agonists may help treat alcohol addiction. In ...

showed improvements in certain measures of alcohol use disorder during a nine-week trial. The Danish drugmaker is also testing semaglutide - sold as the diabetes drug Ozempic and the obesity drug ...

GLP-1 RA use linked to lower risks for myelodysplastic syndromes, myeloproliferative neoplasms compared with metformin. HealthDay News — For patients with type 2 diabetes (T2D), glucagon-like ...